Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 8, 2006, Pages 386-392

  Cho, H Y ^a   Kang, H A ^a   Lee, Y B ^a  

^a Chonnam National University   (South Korea)

Author keywords

Bioequicvalence; Gabapentin; Korean study; Oral product dissolution test; Pharmacokinetics

Indexed keywords

GABAPENTIN; GABATIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TOLERABILITY; FLUORESCENCE ANALYSIS; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KOREA; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNITED STATES; VOLUNTEER;

EID: 33747038652     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44386     Document Type: Article

References (23)

1. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, Sedman AJ. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994; 56: 154-159.
2. CDER/FDA. Guidance for Industry, Bioanalytical Method Validation. 2001.
3. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker; 1992.
4. Elwes RDC, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Clin Pharmacokinet. 1996; 30: 403-415.
5. Forrest G, Sills GJ, Leach JP, Brodie MJ. Determination of gabapentin in plasma by high-performance liquid chromatography. J Chromatogr B. 1996; 681: 421-425.
6. Gibaldi M, Perrier D. Pharmacokinetics (2nd ed). New York: Marcel Dekker; 1982.
7. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bloavailability. Epilepsy Res. 2000; 40: 123-127.
8. Goa KL, Sorkin EM. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993; 46: 409-427.
9. KFDA. Guideline for Bioequivalence. Test 2002.
10. Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm. 1984; 12: 649-655.
11. Mandallaz D, Mau J. Comparison of different methods of decision making in bioequivalence assessment. Biometrics. 1981; 37: 213-222.
12. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia. 1999; 40 (Suppl 6): S39-S50.
13. McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clin Ther. 2003; 25: 1382-1406.
14. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia. 1999; 40 (Suppl 9): S7-S13.
15. Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D. Mucosal uptake of gabapentin (Neurontin) vs. pregabalin in the small intestine. Pharm Res. 2001; 18: 1126-1130.
16. Radulovic LL, Turck D, von Hodenbetg A, Vollmer KO, McNally WP, Dehart PD, Hanson BJ, Bockbrader HN, Chang Y. Disposition of gabapentin (Neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos. 1995; 23: 441-448.
17. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled study. JAMA. 1998; 280: 1837-1842.
18. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, Mckay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - A revisit with a decade of progress. Pharm Res. 2000; 17: 1551-1557.
19. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993; 10: 276-281.
20. USP XXVI. 2003; 2155.
21. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharm Ther. 1995; 67: 351-384.
22. Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci. 1972; 61: 1340-1341.
23. Zhu Z, Neirinck L. High-performance liquid chromatographic method for the determination of gabapentin in human plasma. J Chromatogr B. 2002; 779: 307-312.